We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

34 hedge funds and large institutions have $536K invested in Aspire Biopharma Warrant in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less funds holding

Funds holding: 35 → 34 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

35% less capital invested

Capital invested by funds: $823K → $536K (-$287K)

Holders
34
Holders Change
-1
Holders Change %
-2.86%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
4
Calls
$714K
Puts
–
Net Calls
+$714K
Net Calls Change
-$1.5M

Top Buyers

Rank Fund Capital Flow
1
FPA
First Pacific Advisors
California
+$1.11K
2
FSI
Flow State Investments
Illinois
+$528

Top Sellers

Rank Fund Capital Flow
1
SFM
Spartan Fund Management
Canada
-$11.2K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.43K
3
BI
Bulldog Investors
New Jersey
-$634
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$236K – – –
PC
2
Periscope Capital
Ontario, Canada
$44K – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$31.6K – – –
LA
4
Linden Advisors
New York
$30.5K – – –
SCM
5
Saba Capital Management
New York
$29.6K – – –
HCM
6
Highbridge Capital Management
New York
$25.5K – – –
AA
7
AQR Arbitrage
Connecticut
$19.5K – – –
SC
8
Sculptor Capital
New York
$17.3K – – –
Verition Fund Management
9
Verition Fund Management
Connecticut
$13K – – –
WAM
10
Wolverine Asset Management
Illinois
$12.1K – – –
Barclays
11
Barclays
United Kingdom
$10.5K – – –
TCA
12
Taconic Capital Advisors
New York
$9.03K – – –
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$6.02K – – –
CCM
14
Context Capital Management
California
$5.27K – – –
Nomura Holdings
15
Nomura Holdings
Japan
$4.5K – – –
PAMP
16
Polar Asset Management Partners
Ontario, Canada
$4.17K – – –
EAM
17
Exos Asset Management
New York
$4.12K +$5.36K +137,000 New
LP
18
LMR Partners
United Kingdom
$3.76K – – –
WA
19
Whitebox Advisors
Minnesota
$3.76K – – –
FSI
20
Flow State Investments
Illinois
$3.42K +$528 +13,498 +13%
CSD
21
Clear Street Derivatives
New York
$3.19K +$4.14K +106,000 New
JP Morgan Chase
22
JP Morgan Chase
New York
$3.01K – – –
KL
23
KIM LLC
Kansas
$3.01K – – –
CCM
24
CAAS Capital Management
New York
$2.26K – – –
CS
25
Clear Street
New York
$1.6K – – –
1
2

ASBPW Hedge Fund Activity: Q1 2024 in Review

34 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q1 2024, worth a combined $536K — down 35% from $823K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ASBPW and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was First Pacific Advisors, opening a new position worth an estimated $1.11K. The largest seller was Spartan Fund Management, exiting entirely with an estimated $11.2K sold.

  • 34 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q1 2024, down from 35 in Q4 2023.
  • Funds reported $536K of Aspire Biopharma Warrant stock for Q1 2024, down 35% quarter-over-quarter.
  • 3 funds opened new Aspire Biopharma Warrant positions in Q1 2024 and 4 closed out, a net change of -1 holder.
  • The largest Aspire Biopharma Warrant buyer in Q1 2024 was First Pacific Advisors, an estimated $1.11K added.
  • The largest Aspire Biopharma Warrant seller in Q1 2024 was Spartan Fund Management, an estimated $11.2K sold.

Based on aggregated 13F filings for Q1 2024.